BRAND NAME DISCOUNTS TO PBMs MAY NOT BE LONG-TERM
Executive Summary
BRAND NAME DISCOUNTS TO PBMs MAY NOT BE LONG-TERM cost control mechanism and are "not likely to continue" if pharmaceutical benefit management companies "become the dominant payer in the prescription market," according to a report by PRIME Institute Director Stephen Schondelmeyer, PhD. The report, entitled "Competition and Pricing Issues in the Pharmaceutical Market," was released at an Aug, 4 press conference sponsored by NARD and the National Association of Chain Drug Stores.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth